Abstracts tagged "randomized trials"

Abstract Number: 3134 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease
Dinesh Khanna¹, Carlo Albera², Aryeh Fischer³, James R. Seibold⁴, Nader A. Khalidi⁵, Ganesh Raghu⁶, Lorinda Chung⁷, Elena Schiopu¹, Dan Chen⁸ and Eduard Gorina⁹, ¹University of Michigan, Ann Arbor, MI, ²University of Turin, Turin, Italy, ³National Jewish Health and University of Colorado, Denver, CO, ⁴Scleroderma Research Consultants LLC, Litchfield, CT, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Washington, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Jazz Pharmaceuticals (formerly of InterMune), Palo Alto, CA, ⁹Formerly of InterMune, Brisbane, CA
Background/Purpose: Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). Pirfenidone, a novel antifibrotic agent, has been shown to be…
Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
Jonas K Eriksson¹, Heather Miller², Johan A Karlsson³, Ingemar F Petersson⁴, Sofia Ernestam⁵, Pierre Geborek³, Ronald F van Vollenhoven² and Martin Neovius¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Section of Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Department of Learning, Informatics and Medical Education (LIME), Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…
Abstract Number: 2337 • 2014 ACR/ARHP Annual Meeting
The Cost and Effectiveness of Various Recruitment Strategies in a Mind Body Clinical Trial Among Older Adults with Knee Osteoarthritis
Jade V. Goldsmith¹, Lori Lyn Price², Jeffrey B. Driban³, William F. Harvey³ and Chenchen Wang³, ¹Center for Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ³Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose : Recruitment and adherence are important and challenging factors that can determine the success of a clinical trial. Mind body therapies are an emerging and…
Abstract Number: 2139 • 2014 ACR/ARHP Annual Meeting
Predictors of Radiologic Disease Progression during the Rheumatoid Arthritis Comparison of Active Therapies Trial
Alan Erickson¹, Denis Rybin², Mary Brophy³, Robert Lew³, Ted R. Mikuls¹, Timothy Moore⁴, Keri Hannagan², Edward Keystone⁵ and James O' Dell¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²MAVERIC, VA Boston Heathcare System, Boston, MA, ³VA Boston Heathcare System, Boston, MA, ⁴Radiology, University of Nebraska Medical Center, Omaha, NE, ⁵University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose Halting joint damage is a central goal in the treatment of rheumatoid arthritis. Much research has been conducted to identify factors associated with progressive…
Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
G. R. Burmester¹, C Charles-Schoeman², J. D. Isaacs³, T. Hendrikx⁴, K. Kwok⁵, S. H. Zwillich⁶ and R. Riese⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²University of California, Los Angeles, CA, ³Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Pfizer BV, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
S. B. Cohen¹, Roy Fleischmann¹, J. M. Kremer², A. Koenig³, K. Kwok⁴, L. Wang⁵, C. a. Mebus⁵, R. Riese⁵ and T. Robinson³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
M. C. Genovese¹, R. F. van Vollenhoven², B. Wilkinson³, L. Wang³, S. H. Zwillich³, D. Gruben³, B. Benda⁴ and T. V. Jones⁴, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Abstract Number: L9 • 2013 ACR/ARHP Annual Meeting
Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison
Roy Fleischmann¹, E. B. Lee², S Hall³, B. E. Wilkinson⁴, John D. Bradley⁵, D. Gruben⁴, T. Koncz⁶, S. Krishnaswami⁷, G. Wallenstein⁶, S. H. Zwillich⁴ and R.F. van Vollenhoven⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Seoul National University, Seoul, South Korea, ³Cabrini Health and Monash University, Melbourne, Australia, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁸The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of RA. This Phase 3, 24-mo study (ORAL Start; NCT01039688) compared efficacy, including inhibition…
Abstract Number: 2880 • 2013 ACR/ARHP Annual Meeting
Impact Of Different End Points On The Patient Cohort Size Needed To Demonstrate The Efficacy Of a Therapeutic Intervention In Pss. A Post Hoc Analysis Of The Tears Study (Tolerance and efficacy of Rituximab in primary Sjogren Syndrome study)
Valerie devauchelle-Pensec¹, Sandrine jousse-Joulin², Xavier Mariette³, Jean-Marie Berthelot⁴, Aleth Perdriger⁵, Eric Hachulla⁶, Xavier Puechal⁷, Véronique le Guern⁸, Jean Sibilia⁹, Jacques-Eric Gottenberg¹⁰, Laurent Chiche Sr.¹¹, Vincent Goeb¹², Gilles Hayem¹³, Jacques Morel¹⁴, Charles Zarnitsky¹⁵, Jean Jacques Dubost¹⁶, Jacques-Olivier Pers¹⁷, Divi Cornec¹⁸, Raphaèle Seror¹⁹, Emmanuel Nowak²⁰ and Alain Saraux²¹, ¹Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ²Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ³Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Internal Medicine, Lille CEDEX, France, ⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Internal Medicine, CHU Marseille, Marseille, France, ¹²Rheumatology, Amiens University Hospital, Amiens, France, ¹³Rheumatology Unit, Bichat Hospital, Paris, France, ¹⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ¹⁵Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ¹⁷Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ¹⁸Department of rheumatology, Brest Occidentale University, Brest, France, ¹⁹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²⁰CIC, CHU Brest, Brest, France, ²¹Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: To calculate the sample sizes needed in future randomized controlled trials (RCTs) testing a therapeutic intervention in pSS, methodologists usually rely on data obtained…
Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Bruno Fautrel¹, Thao Pham², Jacques Morel³, Toni Alfaiate⁴, Emmanuelle Dernis⁵, Philippe Gaudin⁶, Olivier Brocq⁷, Elisabeth Solau-Gervais⁸, Jean-Marie Berthelot⁹, Jean-Charles Balblanc¹⁰, Xavier Mariette¹¹ and Florence Tubach¹², ¹Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Le Mans Hospital, Le Mans, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Hospital of Princesse Grâce de Monaco, Monaco, France, ⁸Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁹Rheumatology Unit, Nantes University Hospital, Nantes, France, ¹⁰Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹²INSERM, Universite Paris Diderot, Paris, France
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting
Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
V. Strand¹, R. E. Alten², C. I. Nduaka³, R. Riese³, D. Gruben³, S. H. Zwillich³, J. Andrews³ and G. Wallenstein³, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…
Abstract Number: 1977 • 2013 ACR/ARHP Annual Meeting
Remission At 3 Or 6 Months and Radiographic Non-Progression At 12 Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial
V. Strand¹, D. van der Heijde², R. Landewe³, E. B. Lee⁴, B. Wilkinson⁵, S. H. Zwillich⁵, J. Bradley⁵, C. Mebus⁵, B. Benda⁶ and D. Gruben⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Seoul National University, Seoul, South Korea, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of RA. The importance of “treat to target” in RA to attain…
Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting
Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Maria E. Suarez-Almazor² and Mahesh Bavineni³, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Internal Medicine, Louisiana State University Lafayette, Lafayette, LA
Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
J. M. Kremer¹, J. D. Greenberg², C. Turesson³, D. Gruben⁴, C. A. Mebus⁴, E. Bananis⁵ and T. Robinson⁶, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ³Lund University, Malmö, Sweden, ⁴Pfizer Inc, Groton, CT, ⁵Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
Abstract Number: 1419 • 2013 ACR/ARHP Annual Meeting
Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial
Sofie H.M. Manders¹, Wietske Kievit², Herman L.M. Brus³, Hein J. Bernelot Moens⁴, Andre Hartkamp⁵, Reinhard Bos⁶, Elisabeth Brouwer⁷, Henk Visser⁸, Harald E. Vonkeman⁹, Rene Westhovens¹⁰, Mart A.F.J. van de Laar¹¹ and Piet LCM Van Riel¹, ¹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³TweeSteden Ziekenhuis, Tilburg, Netherlands, ⁴Ziekenhuisgroep Twente, Almelo, Netherlands, ⁵Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, ⁶Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Rijnstate, Arnhem, Netherlands, ⁹Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ¹⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ¹¹Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: The best treatment option after a patient has failed a first TNFi is still unknown. Therefore the objective of this randomized open label study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].